Close Menu

People in the News

Apr 13, 2021

Sera Prognostics: Benjamin Jackson

Benjamin Jackson has been appointed as general counsel of Sera Prognostics. He joins the Salt Lake City-based pregnancy health company from Myriad Genetics, where he held the same position.

Apr 13, 2021

ARUP Labs: Sherrie Perkins, Andy Theurer, Tracy George

Sherrie Perkins is retiring as CEO of ARUP Laboratories, effective June 30. Andy Theurer, ARUP's president, has been appointed by the board to replace Perkins. Tracy George will become ARUP's president and remain as its CMO, the Salt Lake City-based company said.

Perkins is a hematopathologist and joined ARUP in 1990 as a fellow, becoming its CEO in 2017. Theurer has been at ARUP for more than 30 years and was its senior vice president and CFO before becoming its president in 2017. He has been on ARUP's executive committee and a board member for more than 20 years, ARUP said. George is a hematopathologist and has been ARUP's CMO since last September. She joined the firm in 2018 as executive director of clinical trials and pharmaDx. Prior to joining ARUP, she was chief of hematopathology at TriCore Reference Laboratories. She was also vice chairwoman of clinical affairs at the University of New Mexico department of pathology.

Apr 12, 2021

ACMG: Susan Klugman, Shweta Dhar, Hutton Kearney, David Stevenson, Jerry Vockley

The American College of Medical Genetics and Genomics has added five new members to its board of directors, including its new president-elect. They will serve six-year terms starting this month.

Susan Klugman is ACMG's president-elect. She is the director of the division of reproductive and medical genetics at Albert Einstein College of Medicine and Montefiore Medical Center. Klugman holds an a bachelor of science in biometry and statistics from Cornell University and an MD from New York University School of Medicine. She is board-certified in clinical genetics and in obstetrics and gynecology.

Shweta Dhar is an associate professor in the department of molecular & human genetics and the department of internal medicine at Baylor College of Medicine. She is a graduate of Nathiba Hargovandas Lakhmichand Municipal Medical College in India and holds an MS in biotechnology from Stephen F. Austin State University in Texas. She is board-certified in clinical genetics and internal medicine.

Hutton Kearney is vice chair of hereditary genomics in the Mayo Clinic Division of Laboratory Genetics and Genomics and an assistant professor of laboratory medicine and pathology. She holds a BS in secondary education from Auburn University and a PhD in genetics and molecular biology from the University of North Carolina at Chapel Hill. She is board-certified in clinical cytogenetics and clinical molecular genetics.

David Stevenson is a professor of pediatrics in the division of medical genetics at Stanford University. He holds a BA in biology from Utah State University and an MD from the University of Utah.

Jerry Vockley is chief of the division of medical genetics and director of the Center for Rare Disease Therapy at UPMC Children's Hospital of Pittsburgh. He holds an undergraduate degree from Carnegie Mellon University as well as an MD and a PhD in genetics from the University of Pennsylvania School of Medicine. He is board-certified in clinical genetics and in clinical biochemical/molecular genetics.

Apr 12, 2021

Castle Biosciences: Kristen Oelschlager

Castle Biosciences has appointed Kristen Oelschlager as chief operating officer. Oelschlager had been serving as the company's chief operations officer since August 2020. Prior to that, she served as senior vice president of clinical operations from January 2018 to August 2020, VP of clinical operations from 2013 to 2018, and executive director of operations from October 2008 to 2013.
Oelschlager also served as director of clinical research for Arizona Pulmonary Specialists from May 1996 to September 2008.
Apr 09, 2021

Micronoma: Jennifer Wargo

Micronoma, a company using signals from the tumor-related microbiome for liquid biopsy-based cancer diagnosis, has appointed Jennifer Wargo to its scientific advisory board. Wargo is a professor of surgical oncology and genomic medicine at the University of Texas MD Anderson Cancer Center.

Apr 05, 2021

Quadrant Biosciences: Brady Millican

Quadrant Biosciences announced Brady Millican has joined the firm as executive VP of sales. He has more than 30 years of experience in sales, marketing, business development, and operations in the medical diagnostics and prognostics space and was most recently chief business officer of Admera Health. Before that, he had senior level sales and marketing positions at Bostwick, Ameripath, and Dianon Laboratories. Based in Syracuse, New York, Quadrant has developed Clarifi ASD, a molecular saliva-based test for autism spectrum disorder, as well as Clarifi COVID-19, a saliva-based test codeveloped with the SUNY Upstate Medical University, which received Emergency Use Authorization from the US Food and Drug Administration in September.

Apr 05, 2021

Akoya Biosciences: Frederick Pla

Akoya Biosciences has appointed Frederic Pla as its chief operating officer. Pla most recently served as chief operating officer at the Parker Institute for Cancer Immunotherapy. Prior to this, Pla served as COO at Genomic Health before its acquisition by Exact Sciences in 2019. He has also served in leadership positions at Life Technologies, GE Healthcare, and NASA.

Mar 31, 2021

Group K Diagnostics: Jay Rosan, Scientific Advisory Baord

Group K Diagnostics has appointed Jay Rosan to its board of directors. He was VP of health innovation for Walgreens. The company also said that it formed a scientific advisory board in late 2020 comprising Francis Waller, Mark Wingertzahn, Peter Fisher, and Patrick Connolly.

Mar 31, 2021

CareDx: Titte Srinivas, Steven Stone, Dustin Leach, Martyn Edney, More

CareDx has appointed Titte Srinivas as vice president of digital development and clinical integration, Steven Stone as VP of KidneyCare, Dustin Leach as VP of customer experience, and Martyn Edney as senior VP and head of human resources.

Srinivas is a transplant nephrologist who joins CareDx from University Hospitals in Cleveland, where he served as the chief of the division of nephrology and hypertension and Peter B. DeOreo Chair in Nephrology and Dialysis. Stone joins CareDx from from Myriad Genetics, where he served as VP of cancer genomics and developed products for personalized medicine in oncology. Leach joins CareDx from Teva Pharmaceuticals, where he most recently served as senior director of patient services – program development. Edney joins CareDx from Iqvia, where he served as VP of HR for the US and Canada.

The company also announced that it has promoted Marica Grskovic to VP of cell transplant therapy, and Jere Ramsey-Lester to VP of HR.

Grskovic joined CareDx nine years ago and has played a role in overseeing the design and development of the company's transplant diagnostic tests. Ramsey-Lester has been with CareDx since 2019, and has served as interim head of HR for the past year. She has held leadership positions in human resources at TreeHouse Foods, ConAgra Foods, and Fiserv.

Mar 31, 2021

Sera Prognostics: Robert Harrison

Pregnancy test firm Sera Prognostics has appointed Robert Harrison as chief information officer. For more than three decades, Harrison has served in senior leadership positions of both public and private companies. Most recently, he served as officer of Myriad Genetics' chief information office. With Myriad Genetics, he directed the information technology integration of four strategic acquisitions and helped facilitate its international business expansion over the past decade. Harrison is a member of the Association for Information Management Utah CIO Council and is a long-standing board member of the Utah Technology Council.

Mar 30, 2021

Paige: Andy Moye, Juan Antonio Retamero

Paige has appointed Andy Moye its chief commercial officer and Juan Antonio Retamero its medical director. Moye has been the head of commercial operations in North America and Latin America for Philips and has held executive roles at companies including Ontada, a division of McKesson, Caris Life Sciences, and WaferGen Biosystems, now part of Takara Bio. Retamero is a pathologist and expert on the use of digital pathology tools for routine clinical diagnosis. He will lead New York-based development strategy and relationships with clinical and health economic leaders.

Mar 30, 2021

Flatiron Health: Carolyn Starrett

Roche subsidiary Flatiron Health announced that Carolyn Starrett, the current leader of the company's oncology business, will take over as CEO effective April 16. She will replace CEO and Cofounder Nat Turner, who is stepping down from Flatiron management. 

Starrett joined the company in 2016 and was previously VP of customer experience and operations at Flatiron. She served as VP of partnerships and business operations and VP of strategic partnerships at Intent Media before joining Flatiron. 

She has also served as a consultant at Boston Consulting Group and as a senior product manager at Jupiter Networks. 

Mar 30, 2021

VolitionRx: Kim Nguyen, Richard Brudnik

VolitionRx announced that Kim Nguyen and Richard Brudnik had been appointed to the company's board of directors, with Nguyen appointed chair of the company's compensation committee and as a member of the nominations and governance committee. Brudnick was appointed as a member of the audit and compensation committees. 

Nguyen is the head of human relations for Google Asia Pacific, covering the tech and portfolio businesses. She has 20 years of global HR experience.

Brudnick is the chief business officer and head of corporate strategy at Codiak BioSciences, a biopharmaceutical company focused on exome-based therapeutics. He has previously served in senior portfolio strategy, corporate development, and business development positions at pharmaceutical companies.

Mar 29, 2021

Foundation Medicine: Brian Alexander

Foundation Medicine announced that Brian Alexander, the company's chief medical officer, would take over as CEO for Cindy Perettie. Perettie has taken on a new role at Roche Diagnostics, the company said.

Alexander joined FMI as senior VP of clinical development in 2018 and was promoted to CMO in 2019. As CMO, Alexander has expanded the company's molecular tumor board program and launched a genomics and health disparities effort, the company said.

Alexander has served as a radiation oncologist at the Dana-Farber Cancer Institute and Brigham and Women's Cancer Center and an associate professor at Harvard Medical School. He is an affiliated researcher at the Massachusetts Institute of Technology's Laboratory for Financial Engineering and affiliated faculty at the Harvard Kennedy School Healthcare Policy Program. 

He was the founding director of the Program in Regulatory Science at Dana-Farber and the Harvard/MIT Center for Regulatory Science. He also cofounded the nonprofit Global Coalition for Adaptive Research and served as a White House fellow and special assistant to the Secretary of Veterans Affairs.  

Mar 29, 2021

Myriad Genetics: Eric Santa, Jeff Borcherding

Myriad Genetics has hired Eric Santa, previously chief revenue officer at UnitedHealth Group's Rally Health, as its new chief growth officer. Santa will report to Myriad CEO Paul Diaz and lead marketing, digital, branding, and communications initiatives that grow the company's presence and reach. He will also spearhead efforts to glean new genetic insights using Myriad's patient database and identify expansion opportunties. 

Additionally, Jeff Borcherding, previously a general manager leading sales and marketing efforts for the GeneSight pharmacogenetic test, has been promoted to senior VP and chief marketing officer within Santa's team. Borcherding will now focus on increasing test volumes and revenues within Myriad's integrated product marketing initiatives.

Mar 26, 2021

Labcorp: Kathryn Wengel

Laboratory Corporation of American has appointed Kathryn Wengel as an independent member of the company's board, effective immediately. Labcorp's board increased to 10 members from nine, as a result. Wengel is currently EVP and chief supply chain officer at Johnson & Johnson. She also is chairman of the board of GS1 Global, which sets and maintains standards for the exchange of business data for global commerce and is on the executive committee of the National Association of Manufacturers.

Mar 25, 2021

LabVantage Solutions: Mikael Hagstrom

LabVantage Solutions has appointed Mikael Hagstrom its CEO. He was most recently CEO and president of MetricStream, a provider of governance, risk, and compliance products and solutions. Before that, he had stints at analytics software firm SAS Institute and was a partner at McKinsey. Hagstrom was chief operating officer at McKinsey Analytics. Somerset, New Jersey-based LabVantage provides laboratory informatics solutions and services.

Mar 24, 2021

Cue Health: John Gallagher, Erica Palsis, Dena Cook

Cue Health announced three additions to its executive leadership team: John Gallagher as CFO, Erica Palsis as general counsel, and Dena Cook as chief communications officer.

Gallagher previously served as CFO of Becton Dickinson's medical segment and treasurer. He has also been in multiple finance leadership roles at GE, Ford Motor Company, and Visteon. 

Palsis was general counsel, corporate secretary, and privacy officer at digital health firm Livongo until it was acquired. She has also served as corporate counsel at Allscripts. 

Cook previously served as executive VP and head of global communication at Mattel, as well as partner and chief communications officer at Reinvent Capital. She was also CEO at international communications firm Brew and senior VP at Zeno Group. 

Mar 23, 2021

Veracyte: Muna Bhanji

Veracyte has appointed Muna Bhanji to its board of directors. Bhanji most recently served as senior VP of global market access and policy, global human health at Merck. She has previously served on the board of Possible Health and the Foundation of Managed Care Pharmacy. Bhanji currently serves on the boards of Ardelyx, Cytokinetics, and Corus International. 

Mar 19, 2021

Exact Sciences: Paul Clancy

Exact Sciences has appointed Paul Clancy as a Class I member of its board. In connection with his appointment, Clancy was also named to the board's audit and finance committee.

Clancy has more than 30 years of experience in financial management and strategic business planning, and served as the executive vice president and CFO of Alexion Pharmaceuticals from July 2017 to November 2019. Prior to joining Alexion, he served in several positions at Biogen, including executive VP of finance and CFO. Before Biogen, Clancy spent 13 years serving in a variety of financial and general management positions at PepsiCo. 

Mar 19, 2021

Everlywell: Regina Benjamin, Jordan Laser, Dana Underwood, Marisa Cruz

Everlywell announced this week a new addition to its board as well as the appointment of a chief laboratory officer, chief product officer, and executive vice president of regulatory and clinical affairs. Regina Benjamin, the former US Surgeon General under Barack Obama, joins Everlywell's board.

Additionally, Jordan Laser was appointed the Austin, Texas-based firm's first chief laboratory officer. He was formerly at Northwell Health, where he led the clinical lab for a three-hospital tertiary medical center. Laser is also a member of the Association for Molecular Pathology's board. Dana Underwood has also been promoted to Everlywell's first chief product officer. He joined the company in 2020 from Johnson & Johnson, where he was its VP and global head of health tech products. Marisa Cruz was named EVP of regulatory and clinical affairs. She was formerly at Limbix. Before that, she was a medical advisor at the US Food and Drug Administration, including senior medical advisor for digital health at FDA's Center for Devices and Radiological Health.

Mar 18, 2021

Illumina: Jay Flatley, John Thompson

Illumina announced that Jay Flatley will step down from the company's board of directors and John Thompson will replace him as chairman of the board, effective May 26.

"This is part of a thoughtful, long-term succession planning process," Illumina said in a statement.

Flatley led Illumina as CEO from 1999 to 2016 and served as executive chair from 2016 to 2019. He spearheaded Illumina's acquisition of Solexa and with it the underlying technology for Illumina's next-generation sequencing systems.

Thompson has served on Illumina's board since 2017. He is a venture partner at Lightspeed Ventures. Previously, he was CEO at Virtual Instruments and Symantec and held senior roles in sales, marketing, and software development in a 28-year career at IBM. Thompson is also chair of Microsoft's board, a position he has held since 2014, and serves on the boards of privately-held Rubrik and Seismic Software. He holds a master's degree in management science from the Massachusetts Institute of Technology's Sloan School of Management.

Mar 18, 2021

Microba Life Sciences: Mark Capone

Mark Capone has joined the board of directors of microbiome diagnostics company Microba Life Sciences as a non-executive director. He is the president and CEO of Precision Medicine Advisors and the former president and CEO of Myriad Genetics. Prior to his time at Myriad, he held various positions at Eli Lilly.

Mar 18, 2021

Aegirbio: Brandon Steele

Swedish diagnostics firm Aegirbio has named Brandon Steele as its new chief commercial officer, responsible for leading the firm's commercial efforts in the US. Steele most recently served as VP of global commercial operations at San Diego-based companion diagnostics developer Invivoscribe. He also held various senior management, sales, and marketing roles at IncellDx, Applied Imaging, Nanogen, Gen-Probe, and Bayer Diagnostics and began his career at Baxter International. 

Mar 18, 2021

Talis Biomedical: Jeryl Hilleman

Point-of-care infectious disease firm Talis Biomedical has appointed Jeryl Hilleman to its board of directors, where she will serve as the chair of the audit committee. Currently, she serves as chairman of the board of Omada Health and is a director of Novocure, SI-Bone, and Minerva Neurosciences. Previously, Hilleman was CFO at multiple publicly traded companies, including Intersect ENT, Ocera Therapeutics, Amyris, Symyx Technologies, and Cytel.